| Company Name: | GlaxoSmithKline PLC | | Ticker Symbol: | GSK | | | WWW Address: | www.gsk.com |
| CEO: | Sir Andrew Witty | | No. of Employees: | 98,681 |
| Common Issue Type: | AD | | Business Description: | GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 51.48 |  -0.99 | - | - | 52.33 | 52.88 | 52.53 | 1913131 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 126,675.0 | 2,460.7 | 0.64 | 2.96 | 2.48 | 19.7 | 4.2 | 54.00 - 41.68 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 52.86 | $ | | PE Ratio - LTM | 19.7 | |
| Market Capitalisation | 126,675.0 | mil |
| Latest Shares Outstanding | 2,460.7 | mil |
| Earnings pS (EPS) | 2.96 | $ |
| Dividend pS (DPS) | 2.48 | ¢ |
| Dividend Yield | 4.2 | % |
| Dividend Payout Ratio | 84 | % |
| Revenue per Employee | 432,835 | $ |
| Effective Tax Rate | 29.1 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 40,248 | mil |
| Domestic Sales | 2,464 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 14.90 | % |
| Gross Profit Margin | 76.1 | % |
| EBITDA Margin | 28.1 | % |
| Pre-Tax Profit Margin | 23.7 | % |
| Assets Turnover | 0.6 | % |
| Return on Assets (ROA) | 10.6 | % |
| Return on Equity (ROE) | 67.9 | % |
| Return on Capital Invested (ROCI) | 18.9 | % |
| Current Ratio | 1.2 | |
| Leverage Ratio (Assets/Equity) | 6.4 | |
| Interest Cover | 9.0 | |
| Total Debt/Equity (Gearing Ratio) | 2.89 | |
| LT Debt/Total Capital | 72.0 | % |
| Working Capital pS | 1.30 | $ |
| Cash pS | 2.37 | $ |
| Book-Value pS | 4.13 | $ |
| Tangible Book-Value pS | -5.07 | $ |
| Cash Flow pS | 3.94 | $ |
| Free Cash Flow pS | -2.07 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 12.79 | |
| Price/Tangible Book Ratio | -10.42 | |
| Price/Cash Flow | 13.4 | |
| Price/Free Cash Flow | -25.5 | |
| P/E as % of Industry Group | 74.0 | % |
| P/E as % of Sector Segment | 106.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 04/23/2013 |
| Dividend Ex-Date | 05/07/2013 |
| Dividend Record Date | 05/09/2013 |
| Dividend Pay Date | 07/10/2013 |
| Dividend Amount | 550 |
| Type of Payment | Cash Payment |
| Dividend Rate | 2.20 |
| Current Dividend Yield | 4.2 |
| 5-Y Average Dividend Yield | 5.0 |
| Payout Ratio | 84.0 |
| 5-Y Average Payout Ratio | 98.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.2 | 103 | 36,428 | 114,758 |
| 4 Weeks | 54.00 | 50.55 | 52.22 | 1.2 | 103 | 30,049 | 540,887 |
| 13 Weeks | 54.00 | 45.00 | 45.30 | 16.7 | 111 | 29,436 | 1,825,012 |
| 26 Weeks | 54.00 | 43.08 | 44.12 | 19.8 | 103 | 26,386 | 3,245,442 |
| 52 Weeks | 54.00 | 41.68 | 45.07 | 17.3 | 96 | 24,562 | 6,091,459 |
| YTD | 54.00 | 43.68 | - | 21.6 | 106 | 26,705 | 3,017,662 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 52.13 | 51.78 | 51.23 | 46.86 | 46.47 | 0.64 | 0.47 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.77 | 2.8 | -2.52 |
| Income | -2.83 | 1.3 | 9.68 |
| Dividend | 3.33 | 39.8 | 7.69 |
| Capital Spending | -6.33 | NA | -8.33 |
| R&D | 1.20 | NA | -2.20 |
| Normalized Inc. | -3.28 | NA | 10.85 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -7.5 | -7.5 | 0.5 |
| Earnings % | -29.8 | -29.8 | -9.5 |
| EPS % | -29.3 | -29.3 | -7.7 |
| EPS $ | -0.25 | -0.25 | -0.25 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -0.30 |
| Current Ratio | 1.0 |
| Quick Ratio (Acid Test) | 0.7 |
| Liquidity Ratio (Cash) | 0.31 |
| Receivables Turnover | 4.9 |
| Average Collection Period | 73 |
| Working Capital/Equity | -2.1 |
| Working Capital pS | -0.07 |
| Cash-Flow pS | 3.71 |
| Free Cash-Flow pS | -2.01 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.84 |
| Financial Leverage Ratio (Assets/Equity) | 7.1 |
| Debt Ratio | 86.0 |
| Total Debt/Equity (Gearing Ratio) | 3.15 |
| LT Debt/Equity | 2.53 |
| LT Debt/Capital Invested | 106.7 |
| LT Debt/Total Liabilities | 41.1 |
| Interest Cover | 9.3 |
| Interest/Capital Invested | 2.92 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 36.62 |
| Tobin's Q Ratio | 1.94 |
| Current P/E Ratio - LTM | 19.70 |
| Enterprise Value (EV)/EBITDA | 15.38 |
| Enterprise Value (EV)/Free Cash Flow | -30.51 |
| Dividend Yield | 4.2 |
| Price/Tangible Book Ratio - LTM | -10.42 |
| Price/Book Ratio - LTM | 12.79 |
| Price/Cash Flow Ratio | 13.4 |
| Price/Free Cash Flow Ratio - LTM | -25.5 |
| Price/Sales Ratio | 3.14 |
| P/E Ratio (1 month ago) - LTM | 19.3 |
| P/E Ratio (26 weeks ago) - LTM | 14.1 |
| P/E Ratio (52 weeks ago) - LTM | 14.3 |
| 5-Y High P/E Ratio | 44.0 |
| 5-Y Low P/E Ratio | 7.8 |
| 5-Y Average P/E Ratio | 19.1 |
| Current P/E Ratio as % of 5-Y Average P/E | 103 |
| P/E as % of Industry Group | 74.0 |
| P/E as % of Sector Segment | 106.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 19.5 |
| PER SHARE FIGURES |
| LT Debt pS | 8.78 |
| Current Liabilities pS | 8.27 |
| Tangible Book Value pS - LTM | -5.07 |
| Book Value pS - LTM | 4.13 |
| Capital Invested pS | 13.45 |
| Cash pS - LTM | 2.37 |
| Cash Flow pS - LTM | 3.94 |
| Free Cash Flow pS - LTM | -2.07 |
| Earnings pS (EPS) | 2.96 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -12.73 |
| Free Cash Flow Margin 5YEAR AVG | 0.76 |
| Net Profit Margin | 17.9 |
| Net Profit Margin - 5YEAR AVRG. | 16.7 |
| Equity Productivity | 4.55 |
| Return on Equity (ROE) | 81.7 |
| Return on Equity (ROE) - 5YEAR AVRG. | 55.6 |
| Capital Invested Productivity | 1.29 |
| Return on Capital Invested (ROCI) | 23.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 20.1 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 11.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | 10.9 |
| Gross Profit Margin | 76.1 |
| Gross Profit Margin - 5YEAR AVRG. | 78.3 |
| EBITDA Margin - LTM | 28.1 |
| EBIT Margin - LTM | 26.7 |
| Pre-Tax Profit Margin | 25.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 23.9 |
| Effective Tax Rate | 29.1 |
| Effective Tax Rate - 5YEAR AVRG. | 31.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 288 |
| Revenue per Employee | 432,835 |
| Net Income per Employee | 77,688 |
| Average Collection Period | 73 |
| Receivables Turnover | 4.9 |
| Day's Inventory Turnover Ratio | 215 |
| Inventory Turnover | 1.7 |
| Inventory/Sales | 15.0 |
| Accounts Payble/Sales | 30.47 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | -214.89 |
| Fixed Assets Turnover | 0.95 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 6.32 |
| Revenue per $ Plant | 3.01 |
| Revenue per $ Common Equity | 4.55 |
| Revenue per $ Capital Invested | 1.29 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 35.5 |
| Research & Devlopment (R&D) as % of Revenue | 15.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 15.0 |
|
|  
| | |  |  | |
| |
